Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
Last trade$257.98
Day change-$3.93 (-1.50%)
Day range$257.36 – $262.39
Volume288,017
Market cap$25.43B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$25.43B
Price / earnings
30.76×
Price / book
3.5×
Price / sales
4.12×
EV / sales
4.35×
EV / EBITDA
15.89×
Profitability
Earnings per share
$8.52
Return on assets
7.72%
Return on equity
11.39%
Dividend yield
0.99%
Liquidity and leverage
Debt / equity
0.26×
Current ratio
2.05×
Quick ratio
1.44×
Cash ratio
0.44×
Cash flow
Price / cash flow
19.72×
Price / free cash flow
27.13×
Free cash flow
$937.3M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for STE, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$1.59B
$1.49B
$1.59B
$1.5B
$1.46B
$1.39B
$1.48B
$1.37B
Cost of revenue
$877.7M
$808.5M
$891.2M
$840.7M
$814.4M
$763.1M
$839.3M
$760.2M
Gross profit
$710.9M
$684.2M
$697.2M
$655.5M
$645.9M
$628M
$641.2M
$610.4M
Selling, general and administrative
$366M
$369.7M
$351.8M
$352.3M
$349.7M
$353.8M
$333.9M
$335.5M
Research and development
$31.5M
$28.6M
$28.8M
$29.5M
$28.2M
$26.4M
$27.6M
$27.4M
Total operating expenses
$415.3M
$398M
$380.3M
$382.2M
$380.3M
$382M
$425M
$365.1M
Operating income
$295.6M
$286.2M
$316.9M
$273.3M
$265.6M
$246M
$216.2M
$245.3M
Interest expense
-$11.2M
-$15.8M
-$15.1M
-$14.9M
-$14.9M
-$15.9M
-$17.2M
-$19.1M
Income before taxes
$288M
$273.5M
$304.5M
$258M
$253.1M
$231.9M
$197.3M
$228.7M
Income taxes
$73.9M
$72.5M
$84.2M
$63.5M
$60.6M
$53.9M
$50.5M
$55.4M
Net income
$214.1M
$201M
$220.3M
$194.5M
$192.5M
$178M
$146M
$173.2M
Net income attributable to common shareholders
$213.7M
$200.1M
$220.2M
$192.9M
$191.9M
$177.4M
$145.6M
$173.5M
EBITDA
$440.3M
$410M
$440M
$395.7M
$389.5M
$367.2M
$353.8M
$373.4M
Basic earnings per share
$2.20
$2.05
$2.25
$1.96
$1.95
$1.80
$1.49
$1.76
Diluted earnings per share
$2.19
$2.04
$2.23
$1.96
$1.94
$1.79
$1.47
$1.75
Recent news
Company coverage with links to the original publishers.
Steris reported Q2 2026 revenue of $1.59 billion, up 8.8% year-over-year, beating the consensus estimate of $1.56 billion by 1.54%. EPS came in at $2.94, exceeding the estimate of $2.67 by 10.11%. The company showed strong performance across most segments, with Life Sciences revenue up 17.7% and Healthcare Products-Consumables up 10.1%. Steris stock has gained 10.9% over the past month and holds a Zacks Rank #2 (Buy) rating.
Steris reported quarterly earnings of $2.94 per share, beating consensus estimates of $2.67 and surpassing year-ago earnings of $2.47. The company also exceeded revenue expectations with $1.59 billion versus consensus of $1.56 billion. Despite strong earnings performance, Steris shares have underperformed the S&P 500 by 19.3% year-to-date. The stock holds a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
STERIS is expected to report Q2 fiscal 2027 revenues of $1.56 billion (up 7.1%) and EPS of $2.67 (up 8.1%) on November 4, 2026. The Healthcare segment should benefit from steady demand and recent acquisitions, while AST faces destocking headwinds. Life Sciences demand and pricing actions are expected to support margins. However, the Zacks model does not predict an earnings beat due to 0.00% Earnings ESP despite a Rank #2 rating.
STERIS (STE) reported Healthcare segment sales growth of 8% to $1.05 billion in fiscal Q1, driven by services and consumables, while AST segment grew 6% to $297.6 million with improved growth expected in H2. The company faces margin pressures from $14 million in tariff costs and inflation, though strong demand persists in healthcare and life sciences markets. Management maintains fiscal 2027 EPS guidance at $11.12 with projected 7.3% revenue growth.
STERIS plc announced a definitive agreement to acquire Xodus Medical, a specialty surgical products company, for $2.1 billion (net purchase price ~$1.8 billion after tax benefits). The acquisition is expected to close by December 31, 2026, and includes potential earnout consideration up to $150 million. Xodus Medical generated approximately $245 million in annual revenue for 2026 with $135 million in adjusted EBIT. STERIS expects the transaction to be accretive to top-line growth, margins, and adjusted earnings.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.69 per share
Declared
Oct 28, 2026
Ex-dividend
Nov 17, 2026
Pay date
Dec 17, 2026
Ex-dividend
Amount / share
Pay date
Type
Sep 4, 2026
$0.69
Sep 25, 2026
recurring
Jun 8, 2026
$0.63
Jun 26, 2026
recurring
Feb 17, 2026
$0.63
Mar 19, 2026
recurring
Nov 18, 2025
$0.63
Dec 18, 2025
recurring
Sep 4, 2025
$0.63
Sep 26, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.